Immunomodulatory Effects of NB-UVB and Steroids in Vitiligo: A Study on CXCL11 and TEMRA Biomarkers
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: NB-UVB twice weekly, NB-UVB + dexamethasone (2.5-3 mg/week).
- Who it may be relevant to
- Registry conditions: Vitiligo, NB-UVB. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Expression of CXCL11 & TEMRA in Serum of Vitiligo Patients Treated With Narrow-band UVB
Overview
this is a prospective, randomized controlled trial (RCT) investigating the immunological effects of narrowband UVB (NB-UVB) phototherapy-both as monotherapy and in combination with oral mini-pulse (OMP) steroids-in non-segmental vitiligo patients. The study evaluates changes in CXCL11 (a chemokine involved in T-cell recruitment) and TEMRA (terminally differentiated effector memory T cells re-expressing CD45RA) levels in serum before and after treatment.
Detailed description
Design:
Randomized controlled trial (RCT) with two parallel arms.
Duration: Six months (including baseline and follow-up assessments).
Setting: Outpatient dermatology clinic at Assiut University Hospital, Egypt.
Objectives:
Compare the immunomodulatory effects of NB-UVB alone vs. NB-UVB + OMP steroids in vitiligo patients.
Assess CXCL11 and TEMRA levels as potential biomarkers for disease activity and treatment response.
Evaluate clinical repigmentation using Vitiligo Extent Score (VES/VESplus).
Methodology:
40 patients with stable non-segmental vitiligo will be enrolled.
20 patients will undergo serum analysis for CXCL11 and TEMRA via ELISA.
Treatment arms:
NB-UVB monotherapy (twice weekly).
NB-UVB + OMP steroids (dexamethasone 2.5-3 mg/week).
Follow-up: Clinical and immunological assessments at baseline and 6 months.
Interventions
- Radiation NB-UVB twice weekly
Standard phototherapy without additional systemic treatment. - Other NB-UVB + dexamethasone (2.5-3 mg/week)
Combination therapy to enhance immunosuppression and repigmentation.
Primary outcome measures
- Change in serum CXCL11 & TEMRA levels [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
Clinically diagnosed non-segmental vitiligo (stable for ≥3 months).
Fitzpatrick skin types III-V (common in the Egyptian population).
No recent systemic therapy for vitiligo (within the last 3 months).
Exclusion criteria
Photosensitivity disorders (e.g., lupus, porphyria).
Pregnancy or breastfeeding.
Active infections, malignancies, or immunosuppressive conditions.
History of hypertrophic scarring or melanoma.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06946069 · Effects of NB-UVB and Steroids